Literature DB >> 11805225

Acute and chronic effects of methamphetamine on tele-methylhistamine levels in mouse brain: selective involvement of the D(2) and not D(3) receptor.

S Morisset1, C Pilon, J Tardivel-Lacombe, D Weinstein, W Rostene, C Betancur, P Sokoloff, J C Schwartz, J M Arrang.   

Abstract

We have explored the role of endogenous dopamine in the control of histaminergic neuron activity in mouse brain regions evaluated by changes in tele-methylhistamine (t-MeHA) levels. In vitro, methamphetamine released [(3)H]noradrenaline but failed to release [(3)H]histamine from synaptosomes. In vivo, methamphetamine enhanced t-MeHA levels by about 2-fold with ED(50) values of approximately 1 mg/kg in caudate putamen, nucleus accumbens, cerebral cortex, and hypothalamus. This response selectively involved the D(2) and not the D(3) receptor as indicated by its blockade by haloperidol and by its persistence after administration of nafadotride, a D(3) receptor preferential ligand, or in (-/-) D(3) receptor-deficient mice. The t-MeHA response to methamphetamine was delayed compared with the locomotor-activating effect of this drug, suggesting that it is of compensatory nature. In agreement, ciproxifan, an inverse agonist known to enhance histamine neuron activity, decreased the hyperlocomotion induced by methamphetamine. Repeated methamphetamine administration resulted in the expected sensitization to the hyperlocomotor effect of the drug but did not modify either the ED(50) or the E(max) regarding t-MeHA levels. However, it resulted in an enhanced basal t-MeHA level (+30-40%), which was sustained for at least 11 days after withdrawal in hypothalamus, striatum, and cerebral cortex and suppressed by haloperidol. Hence, both the acute and chronic administration of methamphetamine enhance histamine neuron activity, presumably in a compensatory manner. Repeated methamphetamine administration also resulted in a modified balance in the opposite influences of dopamine and serotonin on histaminergic neurons as revealed by the enhanced response to haloperidol and abolished response to ketanserin, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805225     DOI: 10.1124/jpet.300.2.621

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.

Authors:  Mark E Bardgett; Natasha N Davis; Patrick J Schultheis; Molly S Griffith
Journal:  Neurobiol Learn Mem       Date:  2010-11-10       Impact factor: 2.877

2.  The psychostimulant and rewarding effects of cocaine in histidine decarboxylase knockout mice do not support the hypothesis of an inhibitory function of histamine on reward.

Authors:  Christian Brabant; Etienne Quertemont; Christelle Anaclet; Jian-Sheng Lin; Hiroshi Ohtsu; Ezio Tirelli
Journal:  Psychopharmacology (Berl)       Date:  2006-10-28       Impact factor: 4.530

3.  Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Authors:  Andrea M Bradford; Kevin M Savage; Declan N C Jones; Mikhail Kalinichev
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

4.  The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.

Authors:  Mark E Bardgett; Megan Points; Jennifer Kleier; Meredith Blankenship; Molly S Griffith
Journal:  Neuropharmacology       Date:  2010-07-16       Impact factor: 5.250

5.  Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists.

Authors:  Aude Burban; Chit Sadakhom; Dominique Dumoulin; Christiane Rose; Gwenaëlle Le Pen; Henriette Frances; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

6.  Histamine H3 receptor agonists decrease hypothalamic histamine levels and increase stereotypical biting in mice challenged with methamphetamine.

Authors:  Junichi Kitanaka; Nobue Kitanaka; F Scott Hall; George R Uhl; Tomohiro Tatsuta; Yoshio Morita; Koh-ichi Tanaka; Nobuyoshi Nishiyama; Motohiko Takemura
Journal:  Neurochem Res       Date:  2011-05-15       Impact factor: 3.996

7.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

8.  Effects of histamine H(3) receptor activation on the behavioral-stimulant effects of methamphetamine and cocaine in mice and squirrel monkeys.

Authors:  Matthew L Banks; Daniel F Manvich; Rayna M Bauzo; Leonard L Howell
Journal:  Pharmacology       Date:  2009-01-15       Impact factor: 2.547

9.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

10.  Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions.

Authors:  Christian Brabant; Livia Alleva; Thierry Grisar; Etienne Quertemont; Bernard Lakaye; Hiroshi Ohtsu; Jian-Sheng Lin; Peter Jatlow; Marina R Picciotto; Ezio Tirelli
Journal:  Psychopharmacology (Berl)       Date:  2008-10-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.